Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552.
Ifosfamide (1.25 g/m2 intravenously/day x 5) with mesna (20% of the ifosfamide dose x six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non-Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29% response rate (9/31) was observed (2 CR and 7 PR) with a median duration of response of 2.5 months. Myelosuppression was dose-limiting. Hemorrhagic cystitis was observed in three patients (10%). Nausea and vomiting was generally mild or moderate. One patient developed transient neurotoxic symptoms with confusion and disorientation. An additional patient developed an anaphylactic-type reaction with shortness of breath and respiratory strider during the fourth course of therapy. Ifosfamide, as a single agent, produces remissions of limited duration in non-Hodgkin's lymphoma in patients in second or third relapse.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D006402:Hematologic Diseases / Q000139:chemically induced; D006417:Hematuria / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008623:Mercaptoethanol / Q000031:analogs & derivatives*; D015080:Mesna / Q000627:therapeutic use*; D008875:Middle Aged
D008623:Mercaptoethanol; D015080:Mesna; D007069:Ifosfamide